Axial Biotherapeutics Doses First Patient in Ph Ib/IIa Trial of AB-2004 for Treatment of Autism Related GI Dysfunction and Behavioral Symptoms

Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, announced on 7/16/19 the dosing of the first patient in its Phase 1b/2a clinical trial of AB-2004. In animal models, AB-2004 has demonstrated the ability to repair leaky gut and improve repetitive behavior, anxiety and Autism Spectrum Disorder (ASD)-related sensorimotor gating deficits by removing key microbial metabolites.